PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...
Cabaletta Bio (NASDAQ:CABA) used a fireside chat at TD Cowen’s 46th Annual Health Care Conference to highlight progress across its autoimmune cell therapy program, with executives emphasizing upcoming ...
To the Editor: We believe that an important myositis-associated autoantibody, which could be of interest in the differential diagnosis, was overlooked by Drs. Korn and Mauiyyedi in their discussion of ...
Please provide your email address to receive an email when new articles are posted on . Autoimmune diseases may be easier to treat than cancers using cell therapy. Studies continue to examine its use ...
Suggested Citation: "4 Scleroderma." National Academies of Sciences, Engineering, and Medicine. 2022. Selected Immune Disorders and Disability. Washington, DC: The ...
(MENAFN- GlobeNewsWire - Nasdaq) – 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results